VIVOSIM LABS INC (VIVS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.28-0.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — move towards profitability and positive free cash flow: FCF yield not reported vs 0% target.
VivoSim Labs develops 3D human tissues for disease study. The company raised capital recently and hired a new commercial chief. Analysts expect 21% revenue growth next year. The stock trades cheaply with a PE of 0.85 versus peers at 21.7.
The company is loss-making and has no clear revenue or profit guidance. Recent share price dropped 47% from highs. Growth estimates are falling and free cash flow is negative. The biotech sector is volatile and competitive.
The price is about 11% above our fair value near $0.81. The market expects 21% revenue growth but 3- and 5-year growth is forecast to decline. Our view is cautious given the lack of clear forward guidance.
Breaks if: no commercial progress or revenue acceleration reported in next year
Breaks if: free cash flow yield remains below -2% beyond next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds to the uncertainty of its long-term thesis.
The market appears to have low expectations for VIVS, as indicated by a premium valuation compared to peers. There is an expectations gap, suggesting that the current valuation may not fully reflect the risks and challenges the company faces.
Fundamentals are likely to remain mixed in the near term. While there is a stated goal of significant revenue growth, recent financial performance has not shown evidence of this growth yet, and the company is still navigating compliance issues with Nasdaq.
The future of VIVS hinges on several factors, including the company's ability to maintain Nasdaq listing compliance and successfully execute its capital-raising initiatives. Additionally, the performance of sector peers could influence investor sentiment and the company's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 15% next year
In the next 1 to 3 years, VIVS will need to address its operational challenges while capitalizing on sector momentum to improve its standing. Not investment advice.